Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

INDP

Indaptus Therapeutics Inc

Apr 24 • 04:00PM ET

2.35

Dollar change -0.14
Percentage change -5.62	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.84	Insider Own	30.87%	Shs Outstand	8.40M	Perf Week	-11.65%
Market Cap	20.07M	Forward P/E	-	EPS next Y	-1.42	Insider Trans	0.00%	Shs Float	5.90M	Perf Month	-5.24%
Income	-15.42M	PEG	-	EPS next Q	-0.57	Inst Own	7.05%	Short Float	1.70%	Perf Quarter	36.12%
Sales	0.00M	P/S	-	EPS this Y	-6.83%	Inst Trans	12.62%	Short Ratio	1.16	Perf Half Y	-5.62%
Book/sh	1.44	P/B	1.63	EPS next Y	27.37%	ROA	-71.76%	Short Interest	0.10M	Perf Year	-9.97%
Cash/sh	1.56	P/C	1.50	EPS next 5Y	-	ROE	-84.04%	52W Range	1.56 - 4.08	Perf YTD	33.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	56.03%	ROI	-126.94%	52W High	-42.40%	Beta	1.43
Dividend TTM	-	Quick Ratio	5.05	Sales past 5Y	0.00%	Gross Margin	-	52W Low	50.64%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	5.05	EPS Y/Y TTM	-5.91%	Oper. Margin	0.00%	RSI (14)	48.27	Volatility	9.41% 10.26%
Employees	7	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-7.83%	Payout	-	Rel Volume	0.58	Prev Close	2.49
Sales Surprise	-	EPS Surprise	14.81%	Sales Q/Q	-	Earnings	Mar 13 BMO	Avg Volume	85.90K	Price	2.35
SMA20	-5.76%	SMA50	7.50%	SMA200	5.81%	Trades		Volume	49,598	Change	-5.62%

Apr-11-24 07:30AM	Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting (GlobeNewswire) +9.13%
Mar-28-24 08:00AM	Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference (GlobeNewswire) -10.04%
Mar-25-24 08:30AM	Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting (GlobeNewswire) +6.90%
Mar-18-24 08:00AM	Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024 (GlobeNewswire)
Mar-13-24 07:30AM	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:30AM	Loading…
Mar-04-24 07:30AM	Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort (GlobeNewswire) +12.92%
Feb-15-24 08:00AM	Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-08-24 08:00AM	Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels (GlobeNewswire)
Jan-04-24 08:00AM	European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology (GlobeNewswire)
Nov-06-23 04:01PM	Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.20%
08:00AM	Indaptus Therapeutics' Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study (GlobeNewswire)
Oct-31-23 09:01AM	Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting (GlobeNewswire)
Sep-27-23 08:00AM	Indaptus Therapeutics to Present at the LD Micro Main Event XVI (GlobeNewswire)
Sep-26-23 08:00AM	Registration Is Now Open For Tribe Publics Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics CEO On Friday, September 29, 2023 (GlobeNewswire) +11.65%
Sep-19-23 08:00AM	Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20 (GlobeNewswire) +7.34%
08:05AM	Loading…
Sep-06-23 08:05AM	Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-14-23 08:00AM	Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.83%
Aug-10-23 08:45AM	Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20 (GlobeNewswire) +22.78%
Aug-07-23 08:00AM	Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer (GlobeNewswire)
Jun-15-23 08:00AM	Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-31-23 08:30AM	Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023 (GlobeNewswire)
May-11-23 07:00AM	Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -9.30%
May-09-23 08:00AM	Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform (GlobeNewswire) -16.18%
May-01-23 08:00AM	Indaptus Therapeutics Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit (GlobeNewswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -8.74%
Apr-20-23 04:05PM	Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023 (GlobeNewswire) -7.83%
Apr-19-23 09:28AM	UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 (GlobeNewswire) +23.17%
08:05AM	Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 (GlobeNewswire)
Apr-17-23 08:00AM	Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform (GlobeNewswire)
Mar-22-23 08:00AM	Indaptus Therapeutics to Present at the Investor Summit Conference (GlobeNewswire)
08:00AM	Loading…
Mar-17-23 08:00AM	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +6.34%
Mar-15-23 08:05AM	Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023 (GlobeNewswire)
Mar-13-23 08:05AM	Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Mar-07-23 08:05AM	Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Feb-14-23 08:00AM	Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Feb-07-23 08:05AM	Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-13-22 07:30AM	Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire) +9.52%
Nov-10-22 04:05PM	Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-18-22 07:00AM	Indaptus Therapeutics to Present at the LD Micro Main Event XV (GlobeNewswire)
Sep-06-22 09:02AM	Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-08-22 08:00AM	Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-09-22 07:00AM	Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-03-22 07:00AM	Indaptus Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-23-22 08:00AM	Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman (GlobeNewswire)
May-19-22 07:00AM	Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors (GlobeNewswire) +18.80%
May-18-22 04:15PM	Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:00AM	Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 12:20PM	Indaptus Therapeutics, Inc. (NASDAQ:INDP) insiders placed bullish bets worth US$2.4m in the last 12 months (Simply Wall St.)
Apr-20-22 07:00AM	Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit (GlobeNewswire)
Mar-23-22 07:00AM	Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-21-22 07:00AM	Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-17-22 07:00AM	Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit (GlobeNewswire) +6.73%
Mar-07-22 07:00AM	Indaptus Therapeutics to Present at 34th Annual ROTH Conference (GlobeNewswire) -7.67%
Jan-14-22 09:38AM	Stratos Wealth Partners, LTD. Buys PowerShares QQQ Trust Ser 1, WisdomTree U.S. ... (GuruFocus.com)
Jan-05-22 07:00AM	Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire) -8.55%
Jan-03-22 07:00AM	Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer (GlobeNewswire) +8.25%
Dec-01-21 08:00AM	Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors (GlobeNewswire) -10.08%
Nov-15-21 07:00AM	Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -9.88%
Nov-04-21 10:51AM	Bullish insiders at Indaptus Therapeutics, Inc. (NASDAQ:INDP) loaded up on US$775k of stock earlier this year (Simply Wall St.)
Sep-15-21 07:00AM	Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent (GlobeNewswire) +52.05%

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Glen R.	10% Owner	Aug 14 '23	Buy	2.34	23,934	56,006	1,190,400	Aug 16 06:01 PM
Anderson Glen R.	10% Owner	Aug 11 '23	Buy	2.12	35,064	74,336	1,166,466	Aug 16 06:01 PM
Anderson Glen R.	10% Owner	Aug 10 '23	Buy	1.94	44,354	86,047	1,131,402	Aug 16 06:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INDP

Indaptus Therapeutics Inc

Upgrade your FINVIZ experience